SCAI Guidelines for the Management of Patent Foramen Ovale

• Published in: Journal of the Society for Cardiovascular Angiography & Interventions Vol. 1; no. 4; p. 100039
• Main Authors: Kavinsky, Clifford J., Szerlip, Molly, Goldsweig, Andrew M., Amin, Zahid, Boudoulas, Konstantinos Dean, Carroll, John D., Coylewright, Megan, Elmariah, Sammy, MacDonald, Lee A., Shah, Atman P., Spies, Christian, Tobis, Jonathan M., Messé, Steven R., Senerth, Emily, Falck-Ytter, Yngve, Babatunde, Ifeoluwa, Morgan, Rebecca L.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2022
• Subjects: TBD; PICO; RCT; DVT; AF; VTE; DCI; GIN; TIA; ASA; RoPE; PE; POS; SCUBA; TBD; PFO; GRADE; DAPT
• ISSN: 2772-9303; 2772-9303
• DOI: 10.1016/j.jscai.2022.100039

Patent foramen ovale (PFO) is a vestigial congenital cardiovascular structure present in around 25% of adults. In most cases, PFO is entirely benign and requires no treatment. However, it may cause serious complications under certain circumstances. These evidence-based guidelines from the Society for Cardiovascular Angiography and Interventions (SCAI) aim to support patients, clinicians, and other stakeholders in decisions about management of PFO. SCAI convened a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The Evidence Foundation, a registered 501(c)(3) nonprofit organization, provided methodological support for the guideline-development process. Following the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, the guideline panel formulated and prioritized clinical questions in population, intervention, comparison, outcome (PICO) format. A separate technical review team of clinical and methodological experts conducted systematic reviews of the evidence, synthesized data, and graded the certainty of the evidence across outcomes. The guideline panel then reconvened to formulate recommendations and supporting remarks informed by the results of the technical review and additional contextual factors described in the GRADE evidence-to-decision framework. The panel agreed on 13 recommendations to address variations on 5 clinical scenarios. Key recommendations address patient selection for PFO closure in the prevention of recurrent PFO-associated stroke, including populations not commonly included in randomized studies, and scenarios where the PFO closure might serve a role in the prevention of other outcomes such as migraine headaches and decompression illness. The panel has also identified future research priorities to advance the field.